LabGenius
ML-driven biologics drug discovery
LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVA™ is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.
